Drugs / AK132
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06166472 | Dec 2023 → Apr 2026 overdue | cancer | Akeso | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-11-08 | Akeso | Results SITC 2024 | MOA首发！康方生物CLDN18.2/CD47双抗新药机制研究成果在SITC年会重磅发布 akesobio.com ↗
临床前结果显示：AK132对CLDN18.2+/CD47+肿瘤细胞具有ADCC（抗体依赖性细胞毒性）、ADCP（抗体依赖性细胞吞噬）和CDC（补体依赖性细胞毒性）效应，从而具有强大的抗肿瘤效果. |
| 2023-09-18 | Akeso | Regulatory 第6个双抗IND！康方生物AK132(Claudin18.2/CD47双抗)治疗晚期实体瘤获批临床 akesobio.com ↗
近日，康方生物（9926.HK）独立自主研发的双特异性抗体新药AK132（Claudin18.2/CD47双抗）治疗晚期恶性实体瘤的临床试验申请，已于近日获得了国家药品监督管理局药品审评中心（NMPA CDE）批准. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-11-08 | Akeso | SITC 2024 | MOA首发！康方生物CLDN18.2/CD47双抗新药机制研究成果在SITC年会重磅发布 akesobio.com ↗ |
| 2023-09-18 | Akeso | 第6个双抗IND！康方生物AK132(Claudin18.2/CD47双抗)治疗晚期实体瘤获批临床 akesobio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AK132 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06166472 ↗ |
| Route | Intravenous | “IV infusion, specified dose on specified days.” NCT06166472 ↗ |
| Target | CD47 | “The Anti-CLDN18.2 and CD47 Bispecific Antibody AK132” NCT06166472 ↗ |
| Target | CLDN18 | “The Anti-CLDN18.2 and CD47 Bispecific Antibody AK132” NCT06166472 ↗ |